Your questions answered Vol 2 - IM Private Clients
Discussion
If anyone has 10 minutes to kill Redline Magazine just uploaded this...
https://www.youtube.com/watch?v=j0M-cpVkKHs
They were here to cover IM British GT Championship testing, so took my Aston to the hills and I got to drive the support car for the rolling shots (given that was my car too!).
Brilliant fun for the day!
https://www.youtube.com/watch?v=j0M-cpVkKHs
They were here to cover IM British GT Championship testing, so took my Aston to the hills and I got to drive the support car for the rolling shots (given that was my car too!).
Brilliant fun for the day!
SimonTheSailor said:
Is PH Equity take a bit of a hit recently?
Morning Simon, yes, it has lost some of its early year gains, but still sits very slightly up on the year date - and on this time last year.For comparison, the S&P 500 is up more the PHE so far in 2023, but it is still down since this time last year.
So PHE has overall returned more over the last year, but lost some of that lead recently, whilst still remaining ahead of the S&P 500, which remains in the red.
JulianPH said:
SimonTheSailor said:
Is PH Equity take a bit of a hit recently?
Morning Simon, yes, it has lost some of its early year gains, but still sits very slightly up on the year date - and on this time last year.For comparison, the S&P 500 is up more the PHE so far in 2023, but it is still down since this time last year.
So PHE has overall returned more over the last year, but lost some of that lead recently, whilst still remaining ahead of the S&P 500, which remains in the red.
CharlesdeGaulle said:
Simpo Two said:
Sorry to hear the departure of Coops. He was very good at dealing with all the 'easy ones' when it wasn't worth troubling the big guns.
Will there be a 'Coops 2' for the mortals to call when they get stuck?
I'm about to post Julian my application, I love crayons!Will there be a 'Coops 2' for the mortals to call when they get stuck?
Continuing jobless claims of 1.718M vs. 1.659M expected and 1.649M prior-eases pressure on the Fed to racket up rate rises. A positive for equity markets, yields off slightly along with the USD.
The idea being more unemployed will take the heat out of wage inflation which in turn takes the heat out of real inflation (CPI). The dollar weakens because yields (interest rates), fall.
The idea being more unemployed will take the heat out of wage inflation which in turn takes the heat out of real inflation (CPI). The dollar weakens because yields (interest rates), fall.
Vertex Pharma has entered stage 1/2 clinical trials for a cure for Type 1 Diabetes. Vertex 264 is an enhancement to Vertex 880(which ceased testing because of an undesirable immune response). The therapy worked however the patients body rejected the stem cells. Enter 264 which cloaks the drug and makes it invisible to the immune system.
A bit of background explained as simply as possible and how 264 will hopefully overcome observed issues.
VX-880 - This procedure utilises pancreatic islet cells grown in a laboratory from pluripotent stem cells, avoiding the need to harvest the cells from an organ donor. Once the cells are ready, they are placed into a patient’s portal vein. This allows for the new islet cell to monitor blood glucose levels and secrete insulin accordingly.
The new release from Vertex has shown the results from a patient who had had type 1 diabetes for over 40 years, had experienced several life-threatening complications to the disease, and showed zero natural insulin production. This patient was utilising approximately 34 units of insulin per day.
Results after 90 days post-procedure showed the patient had decreased their insulin usage 91%, from 34 units per day down to 2.9 units per day. In addition, the patient dropped from their previous 8.6% A1C to a much more recommended 7.2%. The patient was only reported to have received half of the total clinical dose that Vertex plans to utilise, implying that the patient may have had better results given the implementation of the total dose.
A potential downside to this treatment is that, immunosuppressive therapy is needed to help in the prevention of rejection. The risks and benefits of changing between one disease state to a state of immunosuppression with all its side effects is a serious issue. Vertex has reported their involvement in generating a solution to the immunosuppression issue in these patients. They are exploring the idea(264 cloaking!) of creating an encapsulated islet cell that could potentially allow blood and insulin to filter through while simultaneously preventing the influx of immune cells.
The NHS in the UK alone spend £1.81B care costs treating this disease. Globally it's a £10B market
in say index 60 - 60% is equity which I understand and 40% is fixed overseas interest. How does the 40% work?
are these bonds/other interest earning things ie 1 year fixed bonds and with interest rates rising are these also increasing in their payments? or are they a tracker to bonds?
Im hoping that these will be increasing.
Any news on "cash" held earning interest within IM as I remember it being mentioned was being considered.
many thanks.
James
are these bonds/other interest earning things ie 1 year fixed bonds and with interest rates rising are these also increasing in their payments? or are they a tracker to bonds?
Im hoping that these will be increasing.
Any news on "cash" held earning interest within IM as I remember it being mentioned was being considered.
many thanks.
James
Gassing Station | Finance | Top of Page | What's New | My Stuff